Oncology Medical News about serous ovarian cancer

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer
BMC Cancer, 11/04/09

Merritt MA et al. – The malignant potential of serous ovarian tumors, the most common ovarian tumor subtype, varies from benign to low malignant potential (LMP) tumors to frankly invasive cancers. Given the uncertainty about the relationship between these different forms, the authors compared their patterns of gene expression. The results highlight several genes that may play an important role across the spectrum of serous ovarian tumorigenesis.

<< Previous
State-Level Differences in Breast and Cervical Cancer Screening...

Next >>
Comprehensive analyses and characterization of haemophagocytic...

Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09 Relevance Score: 83%

Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review
Critical Reviews in Oncology/Hematology, 11/12/09 Relevance Score: 82%

Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study
Cancer Causes and Control, 10/02/09 Relevance Score: 81%

F-18 FDG PET-CT Findings in a Case of Normal-Sized Ovarian Cancer Syndrome
Clinical Nuclear Medicine, 10/07/09 Relevance Score: 79%

Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
American Journal of Surgical Pathology, 10/27/09 Relevance Score: 78%